Lundbeck, Otsuka announce positive phase III results for Alzheimer's agitation drug
27/06/2022 07:34
COPENHAGEN, June 27 (Reuters) - Danish drugmaker Lundbeck
LUN.CO and Japan's Otsuka Pharmaceutical 4768.T on Monday
announced positive Phase III results for its brexpiprazole drug
used to treat agitation in patients with Alzheimer's-type
dementia.
The two companies are planning a regulatory filing to the
U.S. Food and Drug Administration later in 2022, Lundbeck said
in a statement.
(Reporting by Stine Jacobsen, editing by Terje Solsvik)
((stine.jacobsen@thomsonreuters.com; +45 21 56 90 10; Reuters
Messaging: stine.jacobsen.thomsonreuters.com@reuters.net))